Ulinastatin protects the lungs of COPD rats through the HMGB1/TLR4 signaling pathway

WEI LIU1,2, ZHIGUANG LIU2, WEIDONG ZHANG2 and SHAOXI CAI1

1Chronic Airway Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515; 2Department of Respiratory Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China

Received December 26, 2016; Accepted February 12, 2018

DOI: 10.3892/ol.2018.9123

Abstract. The present study aimed to investigate the protective mechanism of ulinastatin against lung injury. Rat models with chronic obstructive pulmonary disease (COPD) were used to provide guidance for the medical treatment of this disease. The rats were divided into three groups: A control group, a model group and an experimental group (each, n=10). With the exception of the control group, all of the rats were prepared as models of COPD, using the composite molding method of smoking and intratracheal instillation of lipopolysaccharide. The rats in the model group all received a conventional treatment, while the rats in the experimental group received ulinastatin. A small animal lung function detector was used to examine lung function. The forced expiratory volume/sec (FEV) was negatively correlated with the protein expression levels of Toll-like receptor 4 (TLR4) and high mobility group box protein 1 (HMGB1). Real-time fluorescence quantitative polymerase chain reaction and western blot analyses were used to detect TLR4, MyD88 (myeloid differentiation factor 88), TRAF-6 (TNF receptor-associated factor 6), LOX-1 (lectin-type oxidized LDL receptor 1) and HMGB1 mRNA, along with their protein expression levels.

Introduction

Chronic obstructive pulmonary disease (COPD) is a common and chronic respiratory disease. The main feature of COPD is an incomplete irreversible airflow limitation, which is present in the progressive development of the disease. Furthermore, COPD is associated with an inflammatory reaction to harmful gases or particles in the lungs. A previous study has revealed that the incidence rate of COPD increases annually (1), and is expected to become one of the world’s top three causes of pathogenic-associated mortality by 2020 (2). The latest epidemiological survey data revealed that the incidence rate of COPD among people aged ≥40 in China has risen to 9.9% (3). This disease is a major threat to the health of China’s residents, and is also ranked the top disease burden in China (4). A number of the symptoms of COPD can be controlled through drug treatments; however, there is no effective treatment available that can delay or reverse the disease course (5). Therefore, it is of vital importance for a novel effective treatment to be developed.

Ulinastatin is a type of broad-spectrum protease inhibitor (6). It has the ability to inhibit the activity of glycohydrolase, lipid hydrolase and protease through numerous pathways, as well as to restrain the excessive release of inflammatory mediators, including TNF-α, IL-6 and IL-8, thus reducing the tissue damage (6). A number of studies have revealed that ulinastatin...
may have the ability to prevent the development of acute lung injury, by inhibiting the release of inflammatory mediators (7-9); therefore, it is widely used in the clinical treatment of acute lung injury (10). The occurrence and development of COPD is closely associated with the inflammatory reaction, and the symptoms of the majority of patients are unable to be alleviated during the acute exacerbation of COPD. Ulinastatin has not been previously used in a study on its effects in COPD; therefore, this study used COPD rat models. The rats were given ulinastatin treatment, to determine whether it has a protective effect on lung injury in COPD.

The high mobility group box protein 1 (HMGB1) is distributed in the nuclei and cytoplasm of numerous different types of cells (11). In 1999, Wang et al (12) revealed for the first time, to the best of our knowledge, that HMGB1 is involved in sepsis, and can be considered an important inflammatory mediator. A number of previous studies revealed that ulinastatin could inhibit the release of the inflammatory mediator HMGB1 (8,13,14), and, therefore, it could be associated with COPD due to the high expression of HMGB1 in COPD (15). Toll-like receptor 4 (TLR4) is the receptor for HMGB1; the pro-inflammatory role of HMGB1 is closely associated with the TLR4 signal transduction pathway (16,17). When the HMGB1/TLR4 signaling pathway is activated, HMGB1 binds to and activates TLR4. The activated TLR4 then binds with the TLR4 receptor on myeloid differentiation factor 88 (MyD88) with the aid of MD-2. MyD88 activates IRAK through its death domain, which then activates tumor necrosis factor-receptor-associated factor (TRAF6). TRAF6 can activate the nuclear factor κB (NF-κB) signaling pathway, mediated by the downstream associated factors. This causes the upregulation of lectin-type oxidized LDL receptor 1 (LOX-1), mediating the inflammatory response (18). A previous study revealed that knocking out the TLR4 gene using small interfering RNA could alleviate the inflammatory reaction induced by HMGB1 (19). In the present study, the expression of key molecules associated with the HMGB1/TLR4 signaling pathway was evaluated in lung tissues of COPD rats, in response to treatment with ulinastatin. The mechanism of action of this drug was partially explored, in order to provide a theoretical basis for the effect of ulinastatin in the clinical treatment of COPD.

Materials and methods

**Instruments and reagents.** Lipopolysaccharide (LPS) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany); mortar and grinding rods were purchased from Jiangsu Shunhe Teaching Instrument Co., Ltd. (Jiangsu, China); ulinastatin was purchased from Guangdong Techpool Bio-Pharma Co., Ltd. (Guangzhou, China); the RNA extraction reagent TRizol® was purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA), reverse transcription kit (cat no. 6110A), the fluorescence RT-qPCR kit (cat no. 639676) was purchased from Takara Biotechnology Co., Ltd. (Dalian, China); all primers were synthesized by Shanghai Shenggong Biological Engineering Technology Service, Ltd. (Shanghai, China); chloroform, isopropanol, DEPC water, anhydrous ethanol, agarose were purchased from Shanghai Shenggong Biological Engineering Technology Service, Ltd.; Nanodrop2000 Protein Nucleic Acid Analyzer was purchased from Thermo Fisher Scientific, Inc.; the agarose gel electrophoresis imaging system was purchased from Biometra GmbH (Göttingen, Germany); the ViiA™ 7 fluorescent RT-qPCR machine was purchased from Applied Biosystems (Thermo Fisher Scientific, Inc.); the flexiVent animal lung function instrument was purchased from SCIREQ Inc. (Montreal, Canada); the RIPA cell lysate (cat no. 20101ES60) and PMSF were purchased from Shanghai Biyuntian Bio-technology Co., Ltd. (Shanghai, China); S-18KS handheld microelectromotive tissue homogenizer was purchased from Leptue Scientific Instruments (Beijing) Co., Ltd. (Beijing, China); the total protein extraction kit was purchased from BestBio, Co. (Shanghai, China); the Coomassie Brilliant Blue protein determination kit was purchased from Shanghai Majorbio Bio-pharm Technology Co., Ltd. (Shanghai, China); the SDS-polyacrylamide, PBST solution, vertical electrophoresis apparatus and GIS-2020D gel image analysis system were purchased from Sigma-Aldrich; superSignal™ chemiluminescence substrate was purchased from Thermo Fisher Scientific, Inc.; nitrocellulose membrane, developer, fixer and film were purchased from China Lucky Film Group Corporation (Baoding, Hebei, China); TLR4 (cat no. ab13556), MyD88 (cat no. ab2064), TRAF-6 (cat no. ab33915), LOX-1 (cat no. ab60178), HMGB1 (cat no. ab18256), GAPDH (cat no. ab8245) and Horseradish Peroxidase (HRP)-conjugated rabbit anti-mouse IgG secondary antibody (ab6728) were purchased from Abcam (Cambridge, MA, USA).

**Preparation of the animal models.** A total of 30 healthy, specific-pathogen-free, male adult Sprague-Dawley® rats with a weight range of 180-200 g, 2-3 months of age were provided by the Guangdong Medical Lab Animal Center (Foshan, China). The rats were housed at a temperature of 20-25°C, a humidity of 50-65% a 12 h light/dark cycle and given free access to food and water. The rats were fed adaptively for one week, and randomly divided into three groups: A control group, a model group and an experimental group, with each group containing 10 rats. The method of establishing a COPD rat model was as follows: At days 1 and 14, the rats were injected with 0.2 ml (200 μg) LPS solution (1 g/l) in the trachea through a tracheal intubation under a 10% chloral hydrate anesthesia (according to a 3 ml/Kg dose). Rats were then vertically rotated in order to uniformly distribute the LPS in the lung. Following on, the rats were placed in a homemade glass box in the morning of days 2-13 and days 15-28, where they continuously inhaled cigarette smoke for 1 h/day. The rats in the control group were injected with the same volume of saline through the trachea, but did not inhale any cigarette smoke. The rats in the model group received conventional treatments available for COPD, including expelling phlegm, improving ventilation and antibiotic regimes, whereas rats in the experimental group received 100,000 U/each time of ulinastatin intravenously twice a day for seven days. Upon completion, the lung function was detected using the small animal lung function detector. Following this, the rats were sacrificed after one week, and the lung tissues were removed and stored at -80°C for subsequent experiments. The experimental program in this study was examined and ethically approved by the Laboratory Animal Ethics Committee.

**RNA extraction and RT-qPCR analysis.** Total RNA in the lung tissue was extracted using a TRIzol® kit. The lung tissue was
After the 6‑12% gradient SDS‑PAGE was prepared, 40 µl of the obtained supernatant was collected to obtain total lung tissue proteins. The supernatant was washed twice and then dissolved in DEPC water. The RNA purity and content detected using a protein nucleic acid detection kit. Subsequently, 1% agarose gel electrophoresis was conducted to identify the integrity of the RNA. Following this, 1 µg RNA was used to synthesize cDNA via RT, using a Reverse Transcription kit (fluorescence RT‑qPCR kit), according to the manufacturer’s protocol.

In the reverse transcription reaction system a total volume of 10 µl reaction mixture was used, including 1 µg total RNA, 2 µl of 5X reverse transcriptase buffer, 0.5 µl dT oligo (dT) and Random Primer Mix, 0.5 µl RT Enzyme Mix, 0.5 µl RNase inhibitor, and supplemental ddH2O to bring the total volume up to 10 µl. The reaction conditions were as follows: 37°C for 15 min and 98°C for 5 min. The cDNA produced was stored at -20°C for later use. The cDNA was then used as a template, the fluorescence RT-qPCR reaction system was set as follows: 5 µl of 2X SYBR® Green Mixture, 0.5 µl cDNA, 0.5 µl Primer F (10 µM), 0.5 µl Primer R (10 µM) and 4 µl ddH2O. The reaction conditions were set as follows: Pre-denaturing at 95°C for 10 min, 40 PCR cycles of denaturing at 95°C for 15 sec, and annealing and extension at 60°C for 60 sec. The reactions were processed in a ViiA™ 7 fluorescence RT-qPCR instrument using the 2−ΔΔCq method (20). Overall, three parallel samples were set as replicates for each experiment, with GAPDH as the internal control gene. The sequences of the specific primers are depicted in Table I.

**Protein extraction and western blot analysis.** The obtained lung tissues were homogenized in a homogenizer. After being placed on ice for 30 min, the samples were centrifuged at 13,400 x g, and centrifuged at 30°C for 4 min. The supernatant was collected to obtain total lung tissue proteins. The proteins were quantified with a BCA Protein Quantitation kit, and the total protein was stored at -80°C for later use. After the 6‑12% gradient SDS-PAGE was prepared, 40 µg protein samples were loaded for electrophoretic separation (100 V, 4 h). The protein gels were then placed into a transferring electrophoresis chamber, and transferred at 100 V for 1.5 h with the added transferring buffer. The transferred membranes were blocked for 2 h on a shaker at room temperature, in PBST containing 5% skim‑milk powder. After rinsing with PBST three times, the membranes were incubated at 4°C on a shaker with the primary antibody (1:500 dilution) solution. Following this, PBST was used to rinse the membranes for 30 min; then diluted secondary antibody (diluted 1:10,000) was added, which was diluted with PBST containing 2.5% skimmed milk powder, and incubated at room temperature in a shaker for 60 min. After using PBST to rinse another three times, the nitrocellulose membranes were evenly applied with the chemiluminescence reagent, and underwent exposure in a darkroom. The films were developed in developing reagent for 2 min, rinsed, and then fixed in a fixing reagent for 2 min. The films were further rinsed and hung to dry. The GIS-2020D Gel Imaging Analysis System was used to analyze the optical density of the protein bands of TLR4, MyD88, TRAF-6, LOX-1, HMGB1 and GAPDH. The relative protein expression intensity was defined as the optical density of the protein bands of TLR4, MyD88, TRAF-6, LOX-1, HMGB1 and GAPDH compared with that of GAPDH.

**Statistical analysis.** SPSS 20.0 statistical software (IBM Corp., Armonk, NY, USA) was used for statistical analysis. Measured data were expressed as the mean ± standard deviation. The counted data were expressed as the number of cases or percentage. The comparison between the control group, model group and experimental group was performed using the ANOVA. The comparison between the groups was performed using the Student-Newman-Keuls test. Pearson correlation analysis was used to analyze the correlation between the two sets of data that matched the normal distribution. Spearman correlation analysis was used to analyze the correlation between two sets of data that did not follow the normal distribution. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Effect of ulinastatin on lung function.** As depicted in Table II, the rat lung function indexes, FEV and forced vital capacity were 4057-4063, 2018

### Table I. Forward and reverse upstream primers used in the present study.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Upstream primers, F</th>
<th>Upstream primers, R</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR4</td>
<td>CGCTTTCCAGCTTGTGGCC</td>
<td>CTCCAGAAGAATGTGCCCTC</td>
</tr>
<tr>
<td>MyD88</td>
<td>GCTGACTTGAGCTGTAGCTCTCTTCT</td>
<td>ATGGGTGGGTGGGAGTAAA</td>
</tr>
<tr>
<td>TRAF-6</td>
<td>AGAGGAACTCCTGTGGCACG</td>
<td>TCGTCGGTTCCATTTTGCG</td>
</tr>
<tr>
<td>LOX-1</td>
<td>CTTACCTGGAGAATCTAA</td>
<td>CTCGTCCTTGGATTTCCTG</td>
</tr>
<tr>
<td>HMGB1</td>
<td>ATGGGCGAAGAGATCTCTA</td>
<td>ATTCATCATCATCATCTTCT</td>
</tr>
<tr>
<td>GAPDH</td>
<td>CTGAGCACTCTCCCTCAACATTC</td>
<td>GTGCGACGAACTTTATGTG</td>
</tr>
</tbody>
</table>

TLR4, Toll-like receptor 4; HMGB1, high mobility group box protein 1; MyD88, myeloid differentiation factor 88; TRAF-6, TNF receptor-associated factor 6; LOX-1, lectin-type oxidized LDL receptor 1; F, forward; R, reverse.
(FVC) were significantly lower in the model group compared with in the control group (P<0.05). In the experimental group, FEV and FVC were significantly increased compared with in the control group (P<0.05).

**mRNA and protein expression of TLR4, MYD88, TRAF-6, LOX-1 and HMGB1 in lung tissues.** The mRNA expression levels of TLR4, MyD88, TRAF-6, LOX-1 and HMGB1 were evaluated in the lung tissues of rats from each group. As depicted in the Table III, the mRNA expression levels of all genes were significantly increased in the model group compared with in the control group (P<0.05). In rats from the experimental group with ulinastatin treatment, the mRNA levels are significantly lower when compared with in the model group (P<0.05); however, they are significantly higher when compared with in the control group (P<0.05).

The western blot analyzes reveal a variation of protein expression levels similar to that of the mRNA expression levels (Fig. 1). The protein expression levels of TLR4, MyD88, TRAF-6, LOX-1 and HMGB1 were greater in the model group compared with in the control group (P<0.05). In the lung tissue of rats that received the ulinastatin treatment, the protein expression levels were significantly lower (P<0.05) compared with in the model rats, but remained higher in comparison with the control rats (P<0.05).

**Correlation between the protein expression levels of TLR4 and HMGB1 in the rat lung tissues.** Pearson's correlation analysis was conducted to analyze the correlation between TLR4 and HMGB1 protein expression levels in the lung tissue of the rats (Fig. 2). The results revealed that TLR4 and HMGB1 expression levels exhibit positive correlations in the control group (r=0.764, P=0.010), model group (r=0.814, P=0.004) and experimental group (r=0.805, P=0.005).

**Correlation between TLR4 and HMGB1 expression levels and the lung function of rats.** Spearman's correlation analysis was conducted to analyze the correlation between the rat lung function index FEV, and TLR4 and HMGB1 protein expression levels (Fig. 3). The results reveal that there is a significant negative correlation between FEV, and TLR4 (r=-0.845, P<0.001) and HMGB1 expression levels (r=-0.820, P<0.001).

### Table II. Comparison of inspection results of rat lung function among the groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>FEV&lt;sub&gt;0.3&lt;/sub&gt; (ml)</th>
<th>FVC (ml)</th>
<th>FEV&lt;sub&gt;0.3&lt;/sub&gt;/FVC (%)</th>
<th>PEF (ml.s&lt;sup&gt;-1&lt;/sup&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>5.56±0.31</td>
<td>6.68±0.43</td>
<td>90.10±2.78</td>
<td>36.78±3.89</td>
</tr>
<tr>
<td>Model group</td>
<td>3.89±0.32&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.71±0.39</td>
<td>74.24±2.31&lt;sup&gt;a&lt;/sup&gt;</td>
<td>26.16±3.12</td>
</tr>
<tr>
<td>Experimental group</td>
<td>5.07±0.41&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>6.11±0.45</td>
<td>83.26±2.56&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>32.48±3.26</td>
</tr>
</tbody>
</table>

<sup>a</sup>Model group compared with the control group, P<0.05; experimental group compared with the control group, P<0.05; <sup>b</sup>experimental group compared with the model group, P<0.05. FEV, forced expiratory volume; FVC, forced vital capacity; PEF, peak expiratory flow.

### Table III. Expression of specific mRNAs in rat lung tissues.

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>TLR4</th>
<th>MyD88</th>
<th>TRAF-6</th>
<th>LOX-1</th>
<th>HMGB1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>10</td>
<td>1.00±0.20</td>
<td>1.00±0.18</td>
<td>1.00±0.21</td>
<td>1.00±0.22</td>
<td>1.00±0.19</td>
</tr>
<tr>
<td>Model group</td>
<td>10</td>
<td>2.78±0.31&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.67±0.28&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.34±0.41&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.89±0.29&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.31±0.35&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Experimental group</td>
<td>10</td>
<td>1.67±0.26&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>1.98±0.25&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>1.85±0.36&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>1.38±0.37&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>2.01±0.29&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Model group compared with the control group, P<0.05; experimental group compared with the control group, P<0.05; <sup>b</sup>experimental group compared with the model group, P<0.05. TLR4, Toll-like receptor 4; HMGB1, high mobility group box protein 1; MyD88, myeloid differentiation factor 88; TRAF-6, TNF receptor-associated factor 6; LOX-1, lectin-type oxidized LDL receptor 1.

### Table IV. Expression of certain proteins in the rat lung tissues.

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>TLR4</th>
<th>MyD88</th>
<th>TRAF-6</th>
<th>LOX-1</th>
<th>HMGB1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>10</td>
<td>0.82±0.11</td>
<td>0.56±0.12</td>
<td>0.58±0.14</td>
<td>0.51±0.09</td>
<td>0.79±0.14</td>
</tr>
<tr>
<td>Model group</td>
<td>10</td>
<td>1.21±0.12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.73±0.11&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.76±0.13&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.95±0.10&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.36±0.15&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Experimental group</td>
<td>10</td>
<td>0.93±0.10&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>0.61±0.10&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>0.62±0.10&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>0.72±0.11&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>1.04±0.13&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Model group compared with the control group, P<0.05; experimental group compared with the control group, P<0.05; <sup>b</sup>experimental group compared with the model group, P<0.05. TLR4, Toll-like receptor 4; HMGB1, high mobility group box protein 1; MyD88, myeloid differentiation factor 88; TRAF-6, TNF receptor-associated factor 6; LOX-1, lectin-type oxidized LDL receptor 1.
Currently, it is generally considered that COPD is characterized by chronic inflammation in the airway, lung parenchyma and pulmonary vascular vessels (21). The activated inflammatory cells have the ability to release numerous
inflammatory mediators, which can damage the lung tissue structure and/or promote an inflammatory reaction (22). Therefore, the release of inflammatory mediators serves an important role in the occurrence and development of COPD; in addition, protease/anti-protease imbalance serves an important role in the pathogenesis of COPD (23). Previous studies have revealed that ulinastatin, a type of broad-spectrum protease inhibitor, can reduce tissue damage by inhibiting the release of inflammatory mediators, as observed in acute kidney injury (24), acute pancreatitis (25) and acute lung injury (7,26); however, there are very limited reports on the treatment of COPD with ulinastatin. Therefore, in the present study COPD rat models were established, and underwent ulinastatin treatment, to determine whether ulinastatin had an effect on COPD; which may eventually lead to the elucidation of the underlying disease mechanism.

Pulmonary function tests are the most commonly used clinical indicators to assess COPD lesions, and can confirm the nature, extent and severity of COPD. Measurement of FEV1, FEV1/FVC and peak expiratory flow (PEF) are important clinical indicators of lung function, and can be used to monitor the extent of COPD, and thus guide the selection of treatment (27,28). The present study used the pulmonary function test indicators to evaluate the efficacy of ulinastatin. The results revealed that after the treatment with ulinastatin, the FEV0.3, FVC, FEV0.3/FVC and PEF indexes in the experimental group were significantly higher than those in the model group; this suggests that the rat lung function had improved to a certain extent, and, therefore, that ulinastatin had a protective effect on the lungs of COPD rats. Ulinastatin exerts its inhibitory effect on the activity of various proteases, and carbohydrate and lipid hydrolases, while simultaneously inhibiting the production of oxygen free radicals, thus reducing the oxidative damage to and inflammatory reactions of lung tissues. As HMGB1 is an important cytokine for initiating and maintaining inflammatory reactions, the expressions of HMGB1 and TLR4 signaling pathway-associated molecules, TLR4, MyD88, TRAF-6 and LOX-1, were detected. The results revealed that, compared with in the control group, the mRNA and protein expression levels of TLR4, MyD88, TRAF-6, LOX-1 and HMGB1 were significantly higher in the model group, suggesting that the HMGB1/TLR4 signaling pathway is involved in the occurrence of COPD. After the treatment with ulinastatin, the expression levels of TLR4, MyD88, TRAF-6, LOX-1 and HMGB1 mRNA and protein were significantly decreased in the experimental group, compared with in the model group, and FEV exhibited a significant negative correlation with TLR4 and HMGB1 expression levels. These suggest that the protective effect of ulinastatin on the lungs of the COPD rat is associated with inhibiting the expression of molecules associated with the HMGB1/TLR4 signaling pathway. In a previous study, Ko et al (29) reported that HMGB1 was associated with the occurrence of COPD, and that the serum expression level of HMGB1 had a significant negative correlation with the FEV1/FVC ratio. Kanazawa et al (30) revealed that the HMGB1 content in the epithelial lining fluid of patients with COPD was notably higher than in the healthy control population. The study by Gangemi et al (15) demonstrated that the content of the inflammatory factor HMGB1 in the peripheral blood of patients with COPD was notably elevated. In the present study, the HMGB1 expression in the lung tissues of the COPD model rats was significantly higher than in the control group, indicating that HMGB1 may participate in promoting the onset of COPD. The data are consistent with the studies conducted by Kanazawa et al (30) and Gangemi et al (15). Furthermore, the study by Li et al (31) determined that, compared with in the healthy control population, TLR4 expression in the bronchoalveolar lavage fluid of patients with COPD was significantly high. In the present study, HMGB1 expression was significantly higher in the lung tissues of the COPD model rats, compared with in the control rats, indicating that TLR4 participates in the onset of COPD; these results were similar to those reported by Li et al (31).

Simvastatin is closely associated with the treatment mechanism of COPD. Therefore, in the present study, the focus was on the HMGB1/TLR4 signaling pathway, and the conclusion is that the protective effect of ulinastatin on the lungs of COPD rats may be associated with changes in the HMGB1/TLR4 signaling pathway; however, what it discloses is only the tip of the iceberg in its complex action mechanism. For the better application of ulinastatin in the clinical treatment of COPD, further exploration of the mechanism of action is required.

Acknowledgements

The authors would like to thank Dr. Dajiao Yi (Department of Respiratory Medicine, The Second People's Hospital of Hunan Province, Hunan, China) for their help with animal experiments and revising the manuscript. SC was responsible for the design and modification of experimental protocols, statistical analysis and thesis revision. ZL was responsible for analysis and interpretation of data and materials. WL was responsible for the acquisition of data in animal experiments and drafting the manuscript. WZ was responsible for the statistical analysis, writing and revision of the paper. No funding was received.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

WL was responsible for the acquisition of data in animal experiments and drafting the manuscript. WZ was responsible for the statistical analysis, writing and revision of the paper. ZL was responsible for analysis and interpretation of data in animal experiments and revising the manuscript. SC was responsible for the design and modification of experimental protocols, statistical analysis and thesis revision.
Ethics approval and consent to participate

The experimental program in this study was examined and ethically approved by the Institute Research Ethics Committee at Hunan Provincial People's Hospital (Changsha, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

References


